MicuRx Pharmaceuticals Concludes US Phase I Study for MRX-8
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the conclusion of Phase I...
MicuRx Pharmaceuticals
MicuRx Pharmaceuticals Completes RMB1.06B IPO for Antibacterial Drug Development
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals has officially made an initial public offering (IPO) of...
MicuRx Pharmaceuticals Approved for STAR Market IPO by CSRC
The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) of Sino-US...